SGN-CD123A / Pfizer - LARVOL DELTA

Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. (PubMed, Mol Cancer Ther) - P1; "When combined with a FLT3 inhibitor quizartinib, SGN-CD123A enhanced the activity of quizartinib against two FLT3-mutated xenograft models. Overall, these data demonstrate that SGN-CD123A is a potent anti-leukemic agent, supporting an ongoing trial to evaluate its safety and efficacy in AML patients (NCT02848248)."

Journal • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology

Seattle Genetics reports second quarter 2016 financial results (Seattle Genetics Press Release) -  "Anticipated pipeline programs upcoming activities: [1] Initiate a phase 1 trial of SGN-CD123A in relapsed or refractory AML; [2] Advance SGN-CD352A, a novel ADC for multiple myeloma, into a phase 1 clinical trial. SGN-CD352A targets CD352, and utilizes the company’s PBD and EC-mAb technology."

Anticipated new P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Multiple Myeloma • Oncology

Seattle Genetics: Cowen and Company Global Healthcare Conference (Seattle Genetics, Inc) - Anticipated initiation of P1 trial in AML in 2016

Anticipated new P1 trial • Acute Myelogenous Leukemia • Oncology

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=102; Not yet recruiting; Sponsor: Seattle Genetics, Inc.

New P1 trial • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology